% | $
Quotes you view appear here for quick access.

Antares Pharma Inc. Message Board

  • reality90210 reality90210 Dec 15, 2011 5:00 PM Flag

    "Antares Sell-Off is a Holiday Gift"- Josh Levine

    "After the market close yesterday, Antares Pharma (AIS) partner Biosante reported results from two Phase III efficacy trials for Libigel, which is used to treat hypoactive sexual desire disorder in post-menopausal women. Here's the bottom line: While Libigel was extremely effective and reinforced previous studies, the placebo group fared nearly as well. The failure appears to have been due to a surprisingly high placebo effect. The impact on Biosante is devastating, but it's only a minor bump in the road for Antares. Today's 30%-plus drop in AIS shares is an overreaction and the stock will rebound fully in time."

    He also noted, "Libigel, if successful, would have only begun contributing revenues to Antares in 2015."

    About Josh Levine and Levine's MicroCap

    Josh Levine has 25 years of senior-level experience in analyzing technology trends and investing in top-performing micro- and small-cap stocks.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • IF the companies finances as reported and 'future product' projections are and become accurate, then yesterdays sell off has the potential to be a gift.

      The key will be, can the market refocus on the companys status rather than this news. If so, for those that managed to get some yesterday, should do ok on these shares. May take a while to shake off this 'news', may take NEW news to get folks to even pay attention to AIS in the near term.

      disclaimer: buyer yesterday. Good luck to all.. The hard part is the patience needed to let 'potential winners' run long enough to be 'winners'..

    • This poor SOB must have bought in at the top like me.Now he is going to pump like mad to get out from underwater.Hey what the heck.I'm under water too.

      • 1 Reply to dog_poundd
      • Selling should dry up as the end of the year/quarter approaches. So why not just watch and wait for a while. Obviously it would have been better if the trial had been a success. But there would have been other possible pitfalls down the road. Antares's core business is incremental and perhaps not very exciting. But I think it will add up to a successful company. The negative aura will be dispelled when they turn a profit next year.